Innovation, collaboration, and culture converge in Flemingsberg

This year's Innovation and Collaboration Days in Flemingsberg focused on how innovation, research, and educational collaboration can contribute to a sustainable society, as well as the need for cultural industries in a growing neighborhood.

Innovation, collaboration, and culture converge in Flemingsberg2023-11-10T15:53:53+01:00

Good news for Flemingsberg commuters

Earlier this week, Mitt i Stockholm reported the joyful news that they will be increasing the number of departures on the Södertälje commuter train during rush hours starting from Monday, October 30th. This means that the trains will run eight times per hour.

Good news for Flemingsberg commuters2023-11-02T09:54:04+01:00

Circio, the most advanced company in Europe in circRNA technology, is setting up in new facilities in Flemingsberg

The Norwegian company, Circio Holding ASA, has established a Swedish subsidiary, Circio AB, in Flemingsberg, and they have recently expanded their facilities. The research group and activity level at the Karolinska Institutet grew, necessitating their acquisition of their own labs and offices at A Working Lab in Flemingsberg.

Circio, the most advanced company in Europe in circRNA technology, is setting up in new facilities in Flemingsberg2023-10-09T16:03:23+02:00

Campus Flemingsberg – A Knowledge Hub Shaping the Future Society

At Campus Flemingsberg, nearly 20,000 students study a wide range of subjects, from medical technology and healthcare, to humanities, police training, and music education. It is a place full of knowledge where the foundations of the future society are being laid, and after a pause of three years, the campus day is finally back. It's a day when students and professionals gather at Campus Flemingsberg to kick off the autumn semester together.

Campus Flemingsberg – A Knowledge Hub Shaping the Future Society2023-09-27T10:11:15+02:00

Sprint Bioscience in billion-kronor deal to develop new cancer drug

Sprint Bioscience has licensed its VADA cancer programme to US-based Day One Biopharmaceuticals. The deal is Sprint Bioscience’s largest to date and could be worth around SEK 3.4 billion. In the next two years, the two companies will take the steps towards clinical testing of a new cancer drug.

Sprint Bioscience in billion-kronor deal to develop new cancer drug2023-09-26T16:32:15+02:00
Go to Top